JP7339471B1 - 癌転移抑制用のｖｉｐｒ２アンタゴニストペプチド - Google Patents
癌転移抑制用のｖｉｐｒ２アンタゴニストペプチド Download PDFInfo
- Publication number
- JP7339471B1 JP7339471B1 JP2023528145A JP2023528145A JP7339471B1 JP 7339471 B1 JP7339471 B1 JP 7339471B1 JP 2023528145 A JP2023528145 A JP 2023528145A JP 2023528145 A JP2023528145 A JP 2023528145A JP 7339471 B1 JP7339471 B1 JP 7339471B1
- Authority
- JP
- Japan
- Prior art keywords
- vipr2
- cells
- peptide
- cancer
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022027791 | 2022-02-25 | ||
| JP2022027791 | 2022-02-25 | ||
| PCT/JP2022/047969 WO2023162456A1 (ja) | 2022-02-25 | 2022-12-26 | 癌転移抑制用のｖｉｐｒ２アンタゴニストペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2023162456A1 JPWO2023162456A1 (https=) | 2023-08-31 |
| JP7339471B1 true JP7339471B1 (ja) | 2023-09-05 |
| JPWO2023162456A5 JPWO2023162456A5 (https=) | 2024-01-30 |
Family
ID=87765588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528145A Active JP7339471B1 (ja) | 2022-02-25 | 2022-12-26 | 癌転移抑制用のｖｉｐｒ２アンタゴニストペプチド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250186540A1 (https=) |
| EP (1) | EP4473973A4 (https=) |
| JP (1) | JP7339471B1 (https=) |
| CN (1) | CN118742316A (https=) |
| WO (1) | WO2023162456A1 (https=) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021200259A1 (ja) * | 2020-03-30 | 2021-10-07 | 一丸ファルコス株式会社 | Ｖｉｐｒ２アンタゴニストペプチド |
-
2022
- 2022-12-26 CN CN202280092332.XA patent/CN118742316A/zh active Pending
- 2022-12-26 WO PCT/JP2022/047969 patent/WO2023162456A1/ja not_active Ceased
- 2022-12-26 EP EP22928971.5A patent/EP4473973A4/en active Pending
- 2022-12-26 US US18/841,363 patent/US20250186540A1/en active Pending
- 2022-12-26 JP JP2023528145A patent/JP7339471B1/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021200259A1 (ja) * | 2020-03-30 | 2021-10-07 | 一丸ファルコス株式会社 | Ｖｉｐｒ２アンタゴニストペプチド |
Non-Patent Citations (8)
| Title |
|---|
| LEE Y. et al.，Up-regulation of PI3K/Akt signaling by 17β-estradiol through activation of estrogen receptor-α, but not estrogen receptor-β, and stimulates cell growth in breast cancer cells，Biochemical and Biophysical Research Communications，2005年，336，pp. 1221-1226 |
| LEE Y. ET AL.: "Up-regulation of PI3K/Akt signaling by 17β-estradiol through activation of estrogen receptor-α, bu", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 336, JPN6023010204, 2005, pages 1221 - 1226, XP027230305, ISSN: 0005120289, DOI: 10.1016/j.bbrc.2005.08.256 * |
| SAKAMOTO K. et al.，Generation of KS-133 as a novel bicyclic peptide with a potent and selective VIPR2 antagonist activity that counteracts cognitive decline in a mouse model of psychiatric disorders，Front Pharmacol.，2021年，12，Article 751587, pp.1-15 |
| SAKAMOTO K. ET AL.: "Generation of KS-133 as a novel bicyclic peptide with a potent and selective VIPR2 antagonist activi", FRONT PHARMACOL., vol. 12, JPN6023010202, 2021, pages 751587 - 1, ISSN: 0005120288 * |
| 河原崎 哲, 他5名，癌抑制遺伝子PTENの機能解析，Biotherapy，2004年，18(2)，pp.151-160 |
| 河原崎 哲, 他5名: "癌抑制遺伝子PTENの機能解析", BIOTHERAPY, vol. 18(2), JPN6023010203, 2004, pages 151 - 160, ISSN: 0005120290 * |
| 浅野 智志, 吾郷 由希夫，神経ペプチドVIP-VPAC2 受容体シグナルは，がん細胞遊走を制御する新規の分子機構である，J Oral Biosci.，2021年，Suppl.，p.282, 3-P1-P77 |
| 浅野 智志, 吾郷 由希夫: "神経ペプチドVIP-VPAC2 受容体シグナルは，がん細胞遊走を制御する新規の分子機構である", J ORAL BIOSCI., vol. Suppl., JPN6023010201, 2021, pages 282 - 3, ISSN: 0005120287 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118742316A (zh) | 2024-10-01 |
| EP4473973A4 (en) | 2026-01-21 |
| WO2023162456A1 (ja) | 2023-08-31 |
| EP4473973A1 (en) | 2024-12-11 |
| JPWO2023162456A1 (https=) | 2023-08-31 |
| US20250186540A1 (en) | 2025-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4335910B2 (ja) | メタスチン誘導体およびその使用 | |
| WO2004063221A1 (ja) | メタスチン誘導体およびその用途 | |
| CZ303045B6 (cs) | Deriváty dolastatinu 15 | |
| WO2015056713A1 (ja) | ｃ－Ｍｅｔタンパク質アゴニスト | |
| US20210361741A1 (en) | Nanoparticle formulations and methods of use for alpha connexin c-terminal peptides | |
| JP2025036429A (ja) | プロテアーゼ活性化受容体２のモジュレーター | |
| US20230287051A1 (en) | Inhibitors of complement factor c3 and their medical uses | |
| JP2021510538A (ja) | タンパク質性分子およびその使用 | |
| JP2009523157A (ja) | 虚血および神経変性の処置のための化合物 | |
| US20220227813A1 (en) | Ras INHIBITORY PEPTIDE | |
| JP7339471B1 (ja) | 癌転移抑制用のｖｉｐｒ２アンタゴニストペプチド | |
| US20240391887A1 (en) | New VASHs inhibitors, conjugates thereof and their uses as drugs or as research tools | |
| JP7417010B1 (ja) | 癌免疫増強用のｖｉｐｒ２アンタゴニストペプチド | |
| JP7698318B2 (ja) | Ｖｉｐｒ２アンタゴニストペプチド | |
| CN106170492B (zh) | 环状的Apelin类似物 | |
| JP7464310B2 (ja) | Ｗｎｔシグナル伝達経路の抑制剤 | |
| JP7781422B2 (ja) | Ｃｂ１受容体アゴニストの副作用を軽減するペプチド化合物 | |
| JP2011512364A (ja) | 治療用ペプチド | |
| US20060083742A1 (en) | Prenyl-electrostatic switch, and methods of use | |
| JP7341451B2 (ja) | タンパク質性化合物とその利用 | |
| US20210395310A1 (en) | Cyclic Peptide | |
| WO2025142861A1 (ja) | 組成物 | |
| JPWO2015083816A1 (ja) | 新規ｎｋ３受容体アゴニスト | |
| JPWO1997011091A1 (ja) | 新規ペプチド化合物およびその医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230510 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230510 |
|
| A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A801 Effective date: 20230510 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20230510 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230519 |
|
| A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20230511 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230613 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230801 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230809 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230822 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230824 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7339471 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D03 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |